Abstract: Fibrinogen, involved in coagulation, is a soluble protein composed of two sets of disulfide-bridged Aα, Bβ, and γ-chains. In this review, we present the clinical implications of the αC domain of the molecule in Alzheimer's disease, hereditary renal amyloidosis and a number of thrombotic and hemorrhagic disorders. In Alzheimer's disease, amyloid beta peptide (Aβ) is increased and binds to the αC domain of normal fibrinogen, triggering increased fibrin(ogen) deposition in patients' brain parenchyma. In hereditary renal amyloidosis, fibrinogen is abnormal, with mutations located in the fibrinogen αC domain. The mutant αC domain derived from fibrinogen degradation folds incorrectly so that, in time, aggregates form, leading to amyloid deposits in the kidneys. In these patients, no thrombotic tendency has been observed. Abnormal fibrinogens with either a point mutation in the αC domain or a frameshift mutation resulting in absence of a part of the αC domain are often associated with either thrombotic events or bleeding. Mutation of an amino acid into cysteine (as in fibrinogens Dusart and Caracas V) or a frameshift mutation yielding an unpaired cysteine in the αC domain is often responsible for thrombotic events.
| INTRODUC TI ON
Fibrinogen is a soluble plasma glycoprotein comprising two sets of three chains, disulfide-bridged (Aα-Bβ-γ) 2 . It consists of one central E domain containing the N terminal portions of the Aα, Bβ and γ chains, two lateral D domains connected to the E domain by coiled coils formed by parts of the three chains (Aα 50-160, , and γ 24-134), and two Aα C-terminal domains (Aα 220-610), (αC domains) located outside the D domains ( Figure 1 ). 1, 2 Fibrinogen is converted by thrombin into insoluble fibrin during blood clot formation. First, thrombin catalyzes the release of fibrinopeptides A and B from the Aα and Bβ chains, respectively, to form fibrin monomer. Fibrinopeptide A is released from the Nterminal part of the Aα chain, making accessible a polymerization site "A" that interacts with the complementary "a" site located in the γ chain (T374-E396). 3 The resulting fibrin monomers interact with each other in a half-staggered manner to produce two-stranded protofibrils. 4 Release of fibrinopeptide B, located at the N-terminus of the fibrinogen Bβ chain, unmasks polymerization site "B" to interact with its complementary site "b" located in the C-terminal portion of the Bβ chain, thereby generating fibrin fibers that are associated laterally. 5 In parallel, FXIII activated by thrombin (FXIIIa) catalyzes formation of ε-(γ-glutamyl) lysyl covalent bonds between two γ chains and several α chains of adjacent fibrin molecules, and crosslinks α2-antiplasmin (α2AP), the major plasmin inhibitor, to fibrin. 6 It was further shown that factor XIII also mediates α2AP ligation to plasma fibrinogen on Aα chains prior to initiation of clotting. This process plays an important role in down-regulating the rate of fibrinolysis. 7 Using a homozygous case of dysfibrinogenemia characterized by an amino acid substitution located at the peptide bond on the Aα chain that is normally cleaved by thrombin, it was
shown that clotting of fibrinogen may sometimes occur in absence of fibrinopeptide A release. [8] [9] [10] Recently, it was evidenced that fibrinogen αC domain has several roles in coagulation, mediating its activity during various physiological and pathological processes. αC domain is composed of residues Aα 220-610 consisting of a flexible, unstructured αC connector (Aα 221-391) and a relatively compact C-terminal portion of fibrinogen Aα chain (Aα 392-610).
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In fibrinogen, the two αC domains interact both intramolecularly (ie, with each other) and with the central E region, preferentially through the N termini of the Bβ chains. 2, 12 Initially folded on the N-terminal part of the fibrinogen molecule, the 2 αC domains open outward after fibrinopeptide B (FPB) cleavage, 1, 12 revealing novel cryptic sites for plasminogen and t-PA binding within residues Aα 392-610 of the αC domains 13, 14 and for α2 anti plasmin binding within residues Aα 504-610. 15 Sites also become available for selfassociation of the αC domains into αC polymers, 16 occurring by formation of a hydrogen bond network through their N-terminal subdomains via β-hairpin swapping. This structure is reinforced by interaction of their C-terminal subdomains with the αC connectors, providing the proper orientation of their reactive residues for efficient cross-linking by factor XIIIa. 16 Lateral aggregation may occur in the absence of αC regions, but their presence enhances it. Clots made from fibrinogen lacking αC domains comprise fibers that are thinner and denser, and have more branch points than normal con- found that the conformational change upon conversion of fibrinogen to fibrin results in the exposure of specific epitopes involved in t-PA binding to fibrin; these epitopes are located in Aα 148-160 and γ 312-324.
| Implications of the αC domains in several diseases
It was shown that mutation(s) in the αC domain of fibrinogen may be responsible for severe coagulation disorders, 12 and more recently this domain was also implicated in amyloidosis generation, eg, in
Alzheimer's disease, 20 and familial renal amyloidosis.
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Amyloidosis is caused by abnormal deposition of proteins in soft tissues, and amyloid deposits are primarily made up of protein fibers known as amyloid fibrils. These amyloid fibrils are formed when normally soluble proteins or peptides aggregate and then remain in the tissues instead of being cleared away. Amyloidosis results from a disorder of protein folding characterized by a conformational change of native globular proteins into fibrils with a β-sheet appearance (ie, β strands connected laterally by two or three backbone hydrogen bonds, forming a twisted pleated sheet) that deposit in various organs. 22 In amyloidoses, the deposits contain normal blood proteins and another factor not present in plasma, the amyloidosis-enhancing factor (AEF), novel Aβ-fibrinogen interaction inhibitor rescues both thrombosis and cognitive decline in AD mice.
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As aptly summarized by Cortes-Canteli et al, 43 AD is a multifactorial disorder with a vascular component, and increasing evidence suggests that fibrinogen and fibrin clot formation contribute to this disorder. 44 Fibrin ( as a β-sheet structure; the end result is amyloid deposition in the kidneys. 46 Various renal amyloidogenic mutations in fibrinogen have been described in the literature. [47] [48] [49] [50] [51] [52] [53] These deposits disrupt kidney structure and cause abnormal kidney function, which tends to become progressively more abnormal as amyloid deposits accumulate with time. In these patients, renal histology was characteristic: almost complete glomerular obliteration by amyloid deposition. The disease is characterized by variable penetrance and is associated with hypertension, nephrotic syndrome, proteinuria, and renal failure. Age at onset of symptoms varies from 13 to 70 years. In all cases the clotting times of the variants responsible for renal amyloidosis was normal, except in that reported by Uemichi et al, 51 where thrombin time was slightly prolonged and fibrinogen level was low.
Known amyloidogenic fibrinogen point mutations implicated
in the disease are all located in the αC domain: these include R554L Biochemical analysis of amyloid fibrils from kidneys of the patient with the R554L mutation detected amino acid residues 500-580 of fibrinogen Aα chain. 47 Amyloid fibrils from patients with the E526V mutation contain a similar length peptide fragment from the variant fibrinogen Aα chain only, despite the fact that patients' plasmas contain approximately equal amounts of normal and variant Aα chains; 49 and amyloid fibrils from the patient with a single-nucleotide deletion producing a frameshift at codon 522 are composed of a 49 amino acid fragment of the Aα chain (residues 499-521) followed by a novel sequence created by the frameshift in the patient. in white patients and 13.5% in black patients. 54 The α-fibrinogen T312A variant has been shown to influence clot structure through increased factor XIII cross-linking, since this polymorphism occurs in a region important for FXIII-dependent cross-linking processes, leading to the formation of fibrin clots that could predispose to clot embolization. 55, 56 However, the effect of this common variant on risk of venous thromboembolism (VTE) is unclear for some authors. Characteristics of published mutations are summarized in Tables 1-4 , respectively, corresponding to four types of mutations reported in the literature: single amino-acid substitution in the αC domain;
39-amino-acid duplication in the connector region of the αC domain;
truncations affecting both the αC connector and the αC compact domain; and truncations of the αC compact domain alone.
| Mutants characterized by an amino acid substitution
The first reported case of this type was Dusart syndrome (Table 1) , discovered in one of our patients who presented a severe familial thromboembolic disease and for whom we focused on thrombosis caused by abnormal fibrin structure, since clots from this patient were very tight and could not be degraded by fibrinolytic enzymes. 59 The thromboembolic disease was attributed to impaired fibrin-enhanced plasminogen activation responsible for a defect in fibrin degradability 60 and to an unusual clot rigidity inducing the formation of a brittle clot, therefore resulting in a high incidence of embolism. 61 Further investigation of this fibrinogen variant showed that the anomaly is due to an R554C mutation in the αC domain of fibrinogen that has not been associated with amyloid formation. Other anomalies (n = 15) in the αC domain of the fibrinogen molecule have been described and are presented in Table 1A . [69] [70] [71] [72] [73] [74] [75] [76] [77] Among these cases, four presented thrombotic disorders, another 
| A mutant characterized by elongation of the αC domain
The patient with fibrinogen Champagne au Mont d'Or (Table 2) 
| Mutants characterized by a truncation in the αC connector domain
Most of the patients ( Table 3 ) that presented a frameshift located in the αC connector (Aα 221-391) are homozygous, with a bleeding tendency attributable to either defective factor XIIIa-induced α-chain crosslinks recently identified as Q223-K508, Q223-K539, Q237-K418, Q237-K508, Q237-K539, Q237-K556, Q366-K539, Q563-K539, and Q563-K601, 77, 79, 80, 93 or else to a decrease in factor XIIIa-mediated crosslinking of PAI-2 to several lysines, including Aα K413 and K457, which are associated with hyperfibrinolysis.
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PAI-2 may be undetectable in normal plasma, but it is synthesized by activated monocytes in inflamed tissues, 94 and aligns along fibrin strands, where it may cross-link with fibrin(ogen). 95 Only the patient with France XII dysfibrinogenemia 77 and the double heterozygous Keokuk patient (Aα Q328-stop and guanineto-thymine mutation in Intron 4 of the Aα chain, inducing afibrinogenemia) 79 presented both bleeding and thrombotic episodes secondary to surgery accompanied by infusion of normal fibrinogen.
Heterozygosity for both mutations was required for the expression of severe hypodysfibrinogenemia and for clinical symptoms. 
| Mutants characterized by a truncation within the compact domain of the αC domain
This group of 14 patients with frameshift mutations leading to truncation of the αC compact domain presents a wide variety of clinical outcomes (Table 4) . Severe thrombotic disorders occurred in two cases of homozygous dysfibrinogenemia, fibrinogen Marburg (lacking Aα 461-610) 81 and fibrinogen Milano III (lacking Aα 452-610),
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TA B L E 3 Dysfibrinogenemia due to a frameshift mutation in the fibrinogen αC-connector (Aα 221-391) resulting in a truncation affecting both the connector itself and the Aα compact domain presented with thrombosis, and others with bleeding disorders.
89-91
The patient with fibrinogen Mannheim V presented only with miscarriages. 92 It is interesting to note that similar sequences with a cysteine in position 517 were found in three different abnormal dysfibrinogenemias, ie, San Giovanni Rotondo, 87 Perth, [89] [90] [91] and Mannheim V:
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• Perth mutation Aα P495-LMKLPSSTLPQLEKHSQVSSHL-C517
• Manheim V mutation Aα H494-PLMKLPSSTLPQLEKHSQ VSSHL-C517
• San Giovanni Rotondo mutation Aα A499-SSTLPQLEKHSQV
SSHL-C517
Although they share an identical sequence, and the unpaired cysteine at Aα 517 generated fibrinogen-albumin complexes in all three dysfibrogenemias, the clinical syndromes are different: the propositus with fibrinogen San Giovanni Rotondo is asymptomatic, whereas the patient with fibrinogen Mannheim V had miscarriages-and those with fibrinogen Perth present either thrombotic disorders or a bleeding tendency, as described above.
| Importance of the αC domain in fibrinogen assembly in and/or secretion by hepatocytes
The αC domain seems to be involved in fibrinogen assembly within and/or secretion from hepatocytes, as previously suggested by Ridgway et al 80 and Jayo et al 91 in the case of fibrinogen Otago (lacking amino acids 272-610), the mother (propositus) was homozygous for the mutation and expressed very low fibrinogen TA B L E 4 Dysfibrinogenemia due to truncation caused by a frameshift mutation in the fibrinogen αC compact domain (Aα 392-610) 
| Importance of unpaired Aα cysteine in dysfibrinogenemias
In normal fibrinogen, the αC domains are folded on the N-terminal portion of the fibrinogen molecule and unfold upon fibrin formation, promoting lateral aggregation of protofibrils. In fact it appears that mutation to C of an amino acid located in the αC domain is important for thrombotic disorders. For example, in certain dysfibrinogenemias ( Table 4) In abnormal fibrinogens arising from a frameshift mutation in the αC connector that results in truncation of the Aα chain beginning at amino acid positions 272-328 (Table 3) , there are no unpaired cysteines available to bind albumin (Aα C442 and C472 are absent); this may explain why no thrombosis was reported in these patients. in the course of the disease might be a viable alternative, avoiding the need for hemodialysis and kidney transplantation. 45 In contrast, dysfibrinogenemia associated with thrombotic or hemorrhagic disorders can be adequately managed with anticoagulant therapy or blood transfusion, respectively.
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| PERSPECTIVES
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